BACKGROUND The management of disseminated cysticercosis is unclear and largely considered hazardous. The role of albendazole remains controversial in such patients. METHODS A tertiary care, University hospital-based prospective intervention study was conducted from December 2015 to December 2017. Patients with disseminated cysticercosis, defined as the presence of multiple viable neurocysticerci (≥ 3) in the brain along with involvement of an additional extra site, were included in the study. Patients with cysticercal encephalitis were excluded. A detailed evaluation, including ophthalmoscopy, ocular B scans, ultrasound abdomen, and X-rays were done. Albendazole was administered at a dose of 15 mg/kg/day in 3 cycles of 28 days each. All patients were also given adjuvant corticosteroids and anti-epileptic drugs. Clinical and radiological follow up was carried out at a difference of 3 months between each treatment cycle. For radiological quantification, lesions were counted at 10 pre-specified levels. Statistical analysis was done to estimate the difference in seizure frequency and lesion load. RESULTS Twenty-nine patients (21 with > 20 lesions; 8 with ≤ 20 lesions) were given albendazole as per the protocol. There was a significant reduction in the occurrence of seizures (P < 0.001) and headache (P < 0.001). A significant reduction in lesion load from baseline to third follow-up was seen in the estimations done at different levels (P < 0.001). No patient developed serious side-effect warranting cessation of therapy. CONCLUSION Cyclical use of albendazole appears efficacious in treating disseminated cysticercosis. The method of quantification described may be used in future studies for objective assessment. TRIAL REGISTRATION ISRCTN11630542; 28th September 2019; Retrospectively registered.

中文翻译：

---

弥散性囊尾rc病病灶负荷和3个周期阿苯达唑疗效的定量评估：前瞻性评估。

背景技术弥散性囊尾rc病的治疗尚不清楚，并且被认为是危险的。阿苯达唑在此类患者中的作用仍存在争议。方法2015年12月至2017年12月，进行了一项基于大学医院三级护理的前瞻性干预研究。患有弥散性囊尾osis病的患者定义为大脑中存在多个可行的神经囊尾ci（≥3）并伴有额外的额外部位，被纳入研究。囊性脑炎患者被排除在外。进行了详细的评估，包括检眼镜，B眼检查，腹部超声和X射线检查。阿苯达唑的剂量为15 mg / kg /天，分3个周期，每个周期28天。所有患者还接受了辅助性糖皮质激素和抗癫痫药。每个治疗周期之间相差3个月进行临床和放射学随访。为了进行放射学定量，将病变计数为10个预先指定的水平。进行统计分析以估计癫痫发作频率和病变负荷的差异。结果按照方案，对29例患者（21例> 20个病灶； 8例≤20个病灶）进行了阿苯达唑治疗。癫痫发作（P <0.001）和头痛（P <0.001）的发生显着减少。在不同水平进行的评估中，从基线到第三次随访，病灶负荷显着减少（P <0.001）。没有患者出现严重的副作用，需要停止治疗。结论周期性地使用阿苯达唑可有效治疗弥漫性囊尾appears病。所描述的量化方法可能会在未来的研究中用于客观评估。试注册ISRCTN11630542; 2019年9月28日; 追溯注册。